AKEBIA THERAPEUTICS INC (AKBA) Forecast, Price Target & Analyst Ratings

NASDAQ:AKBA • US00972D1054

Current stock price

1.38 USD
-0.03 (-2.13%)
At close:
1.3798 USD
0 (-0.01%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AKEBIA THERAPEUTICS INC (AKBA).

Forecast Snapshot

Consensus Price Target

Price Target
$4.49
+ 225.22% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.03
Revenue Estimate
52.995M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
87.27%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$4.49
Upside
+ 225.22%
From current price of $1.38 to mean target of $4.49, Based on 11 analyst forecasts
Low
$3.03
Median
$4.08
High
$6.30

Price Target Revisions

1 Month
-4.35%
3 Months
-18.52%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for AKBA. The average price target is 4.49 USD. This implies a price increase of 225.22% is expected in the next year compared to the current price of 1.38.
The average price target has been revised downward by 18.52% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

AKBA Current Analyst RatingAKBA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4

Analyst Ratings History

AKBA Historical Analyst RatingsAKBA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
87.27%
AKBA was analyzed by 11 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about AKBA.
In the previous month the buy percentage consensus was at a similar level.
AKBA was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-02-25BTIGMaintains Buy -> Buy
2026-02-06Piper SandlerMaintains Overweight -> Overweight
2026-02-06HC Wainwright & Co.Reiterate Buy -> Buy
2025-12-02BTIGReiterate Buy -> Buy
2025-12-02HC Wainwright & Co.Reiterate Buy -> Buy
2025-10-30HC Wainwright & Co.Maintains Buy -> Buy
2025-10-29BTIGMaintains Buy -> Buy
2025-04-28Leerink PartnersInitiate Outperform
2025-04-04HC Wainwright & Co.Reiterate Buy -> Buy
2025-04-01JefferiesInitiate Buy
2025-03-14Piper SandlerMaintains Overweight -> Overweight
2025-03-14HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-23HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-14HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-23HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-10HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-08HC Wainwright & Co.Reiterate Buy -> Buy
2024-09-06HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-12HC Wainwright & Co.Maintains Buy -> Buy
2024-03-28HC Wainwright & Co.Maintains Buy -> Buy
2024-03-15HC Wainwright & Co.Reiterate Buy -> Buy
2023-11-17HC Wainwright & Co.Maintains Buy -> Buy
2023-09-27HC Wainwright & Co.Reiterate Buy -> Buy
2023-08-28HC Wainwright & Co.Upgrade Neutral -> Buy
2023-08-11HC Wainwright & Co.Reiterate Neutral -> Neutral

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.03
Revenue Estimate
52.995M
Revenue Q2Q
-7.57%
EPS Q2Q
-202.00%
Number of Analysts
7

Next Earnings Revisions

Revenue (1 Month)
-10.95%
Revenue (3 Months)
-12.43%
EPS (1 Month)
N/A
EPS (3 Months)
-200.00%

Next Earnings Summary

AKBA is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.03 USD and the consensus revenue estimate is 52.99M USD.
The next earnings revenue estimate has been revised downward by 12.43% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
AKBA revenue by date.AKBA revenue by date.
194.623M
-33.46%		160.18M
-17.70%		236.196M
47.46%		236.05M
-0.06%		196.74M
-16.65%		257.41M
30.84%		318.97M
23.92%		432.53M
35.60%		494.1M
14.23%		546M
10.50%		594.68M
8.92%
EBITDA
YoY % growth
AKBA ebitda by date.AKBA ebitda by date.
-6.848M
-329.03%		-8.71M
-27.19%		27.268M
413.07%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
AKBA ebit by date.AKBA ebit by date.
-44.475M
-28.17%		-46.214M
-3.91%		25.999M
156.26%		4.023M
-84.53%		-23.346M
-680.31%		44.614M
291.10%		127.44M
185.65%		222.31M
74.44%		274.09M
23.29%		321.83M
17.42%		362.62M
12.67%
Operating Margin
AKBA operating margin by date.AKBA operating margin by date.
-22.85%-28.85%11.01%1.70%-11.87%17.33%39.95%51.40%55.47%58.94%60.98%
EPS
YoY % growth
AKBA eps by date.AKBA eps by date.
-0.28
36.36%		-0.33
-17.86%		-0.02
93.94%		-0.08
-295.25%		-0.08
-6.45%		0.12
237.37%		0.07
-38.23%		0.18
157.14%		0.36
94.44%		0.55
54.29%		0.72
31.48%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.03
-202.00%		-0.03-0.030.03
161.20%		-0.08
-166.67%		-0.07
-133.33%		-0.06
-87.50%		-0.05
-250.00%
Revenue
Q2Q % growth		52.995M
-7.57%		55.146M
-11.73%		58.014M
-1.28%		69.869M
21.26%		31.875M
-39.85%		36.659M
-33.52%		40.622M
-29.98%		46.971M
-32.77%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-2.314M
-117.38%		-2.725M
-119.48%		-2.731M
-169.15%		11.112M
303.78%		-19.813M
-756.37%		-17.181M
-530.49%		-15.282M
-459.60%		-11.555M
-203.99%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

AKBA Yearly Revenue VS EstimatesAKBA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
AKBA Yearly EPS VS EstimatesAKBA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -1 -2 -3

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
98.15%
EPS Next 5 Year
62.06%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
3.25%
Revenue Next 5 Year
13.09%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

AKEBIA THERAPEUTICS INC / AKBA Forecast FAQ

What is the price target for AKBA stock?

11 analysts have analysed AKBA and the average price target is 4.49 USD. This implies a price increase of 225.22% is expected in the next year compared to the current price of 1.38.

What is the next earnings date for AKBA stock?

AKEBIA THERAPEUTICS INC (AKBA) will report earnings on 2026-05-06.

Can you provide the consensus estimates for AKEBIA THERAPEUTICS INC next earnings?

The consensus EPS estimate for the next earnings of AKEBIA THERAPEUTICS INC (AKBA) is -0.03 USD and the consensus revenue estimate is 52.99M USD.

What is the expected long term growth rate for AKBA stock?

The expected long term growth rate for AKEBIA THERAPEUTICS INC (AKBA) is 3.25%.